UNSPSC 51384604: Bendazac or bendazolic acid

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H14N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G4AG71204O, chemically known as acetic acid, ((1-(phenylmethyl)-1h-indazol-3-yl)oxy)- but generally known as bendazac, which bears US NIH Compound Identifier 2313. Bendazac most often comes in base, lysine, methyl ester, and sodium forms. European Medicines Agency schedules Bendazac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05708MIG.

UNSPSC 51384604 Bendazac or bendazolic acid is a Commodity code that in recent state and local procurement shows minimal activity aligned with its nominal pharmaceutical scope. The single recent opportunity posted under this code — Seminole County, Florida's IFB 60459723LAS issued June 30, 2026 — solicits naloxone and safe drug deactivation systems rather than bendazolic acid itself, indicating a mismatch between the code assignment and the actual goods being procured. Naloxone is an opioid antagonist used in overdose response, and drug deactivation systems are medical waste or pharmaceutical disposal equipment, neither of which falls within the bendazolic acid commodity definition. This suggests either a coding error in the source record or category misalignment in the issuing body's procurement database.

The Seminole County opportunity represents the only recent state and local activity indexed under this code and calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The IFB required electronic submission by July 26, 2023 (note: a historical deadline despite the June 2026 posting date in the source, suggesting data quality issues in the underlying record). Vendors must provide unit costs, maintain workers' compensation and commercial general liability insurance, comply with drug-free workplace and E-Verify requirements, and accept a two-year initial term with one-year renewal option and a three-month probationary termination clause. The contract was potentially funded through FEMA, adding federal compliance requirements. Given the mismatch between the code's pharmaceutical scope and the actual procurement content, this code shows little relevant recent activity for bendazolic acid vendors.